Last reviewed · How we verify

NCT06295354: EVIA-NL

Early Variations in Immune Aging

Terminated Last updated 1 May 2025
What this trial tests

trial testing No intervention, we just study 'aging' in Aging in 1,000 participants. Terminated before completion.

Timeline
7 October 2024
Primary endpoint
27 January 2025
18 March 2025

Quick facts

Lead sponsorRadboud University Medical Center
StatusTerminated
Study typeOBSERVATIONAL
Enrollment1,000
Start date7 October 2024
Primary completion27 January 2025
Estimated completion18 March 2025
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Radboud University Medical Center

Who can join

Adults 20 to 60, any sex, with Aging or Aging Well. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Despite an increase in lifespan over the last decades, our healthspan lags behind. In our aging population, it is pressing that we prevent age-related morbidities and associated burden on the health care system. Instead of investigating aging in already aged populations, the currently proposed study aims to elucidate the process of immune aging in relation to biological aging, demographic and lifestyle factors in young and midlife adults, and to identify early biomarkers and pathways associated with fast versus slow immune aging and aging endotypes. Study design: A single-center, observational prospective cohort study in the Netherlands. Participants from priorly established cohorts will be invited to join the EVIA-study. We will obtain demographic and basic clinical data and biological samples (blood and stool) at baseline and after three years, with a short, yearly online questionnaire in between.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aging

Currently open trials in the same condition.

Other Radboud University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06295354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing